Disclosures. The Montreal Protocol. The Spectrum of Obstructive Lung Disease: Asthma & COPD. The Spectrum of Obstructive Lung Disease: Asthma & COPD
|
|
- Opal Hill
- 5 years ago
- Views:
Transcription
1 The Spectrum of Obstructive Lung Disease: Asthma & COPD Disclosures No Pharma Consulting, Research, Lectures Stephen C. Lazarus, M.D. Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco Advances in Internal Medicine San Francisco, CA June 26, 29 NHLBI - Asthma Clinical Research Network NHLBI - COPD Clinical Research Network NAEPP Coordinating Committee The Spectrum of Obstructive Lung Disease: Asthma & COPD Asthma: CFC-driven MDIs discontinued December 31, 28 Inhaled steroids reduce Asthma Exacerbations Asthma Exacerbations ----> loss of lung function Mild asthma may not require chronic controller Tx Linking ICS to ß-agonist rescue seems to work Pneumococcus, ASA, Vitamin D Anti-Reflux Therapy? Anti-Eosinophil Therapy? The Montreal Protocol International Environmental Treaty Banned CFCs in consumer aerosols US has eliminated almost all manufacture and importation of CFCs since January 1, 1996 Essential use Exemption for: - MDIs for Asthma and COPD - Space Shuttle and Titan Rockets Single ingredient albuterol CFC MDIs banned, effective December 31, 28. 1
2 Short-Acting ß-Adrenergic Agonists New Approach?? Short-Acting ß- Adrenergic Agonist + Inhaled Corticosteroid Fanta, CH N Eng J Med 36:12-14, 29 Beclomethasone vs Montelukast: Time Until First Asthma Attack Health Care Utilization Proportion of Patients Without Asthma Attacks p =.1 beclomethasone compared with placebo p =.6 montelukast compared with placebo p =.129 montelukast compared with beclomethasone Days Since Randomization Beclomethasone Montelukast Malmstrom et al. Ann Intern Med. 1999;13: Rate/1 PY 3 Budesonide 25 Nedocromil P= Hospitalizations P<.1 P= Urgent visits CAMP, NEJM 343: , 2 2
3 FACET Study: Formoterol and Budesonide in Moderate Asthma SOCS - Treatment Failure Rate P = BUD 2 mcg/day BUD 2 mcg/day + Formoterol 24 mcg/day BUD 8 mcg/day BUD 8 mcg/day + Formoterol 24 mcg/dayl Pauwels RA, et al. N Engl J Med. 1997;337: Treatment Failure, % Randomized Treatment Period, wk P=.18 P=.4 Lazarus et al. Asthma Clinical Research Network JAMA 285: , 21 Probability Kaplan-Meier Survival Curves: Withdrawal for Worsening Asthma Advair 25mcg FP 25mcg SALM 5mcg * differs from FP 25mcg, SALM and placebo, p Study Day Shapiro et al. Am J Respir Crit Care Med 2;161: * Q1: Every patient with persistent asthma should receive: 1. Prn ß-agonist 2. Regular ICS + prn ß-agonist 3. Prn ICS + prn ß-agonist 2% 92% 6%
4 Should all patients with asthma be treated regularly with an inhaled corticosteroid? The IMPACT Study IMPACT Protocol Design N = 225 Budesonide Zafirlukast (therapy only as needed) Week Visit All patients were taught to initiate short courses of oral or inhaled corticosteroids by a Symptombased Action Plan* *Coté et al., AJRCCM 1997; 155: 159 Change in AM Peak Flow Change in AM PEF (%) Baseline to End Treatment 1 5 P=.94 Bud Zaf PRN Change in FEV 1 (% Change baseline to end treatment) Pre Albuterol FEV 1 Bud Zaf PRN * FEV 1 (%) Post Albuterol FEV 1 Bud Zaf PRN Boushey et al N Engl J Med 352: , 25 *P =.5 P =.292 Boushey et al N Engl J Med 352: , 25 4
5 Asthma Exacerbation Rates (symptoms warranting course of oral CS) 47.8 wks Controller.48 wks Controller IMPACT: Other Outcomes Changes in Asthma control, Asthma-specific quality of life, and symptom-free days ACQ AQLQ SFD/2wks Budesonide Zafirlukast PRN P=.1 P=.18 P=.3 Boushey et al N Engl J Med 352: , 25 Boushey et al N Engl J Med 352: , 25 IMPACT: Summary In adults with long-standing, mild persistent asthma, who were given medication and a symptom-based action plan, twice daily treatment with budesonide, with zafirlukast, and with placebo over one year did not differ with regard to asthma exacerbations, asthma-specific quality of life, or the rate of loss of lung function over 1 year. IMPACT: Conclusion The criteria for mild persistent asthma may define a condition so mild that the decision as to whether to take regular daily therapy or to take only short courses of inhaled or oral corticosteroid therapy on an as needed basis may be left to the patient s own assessment of the importance of the subjective improvements experienced, and of the cost, inconvenience, and perceived risks of the treatment. Boushey et al N Engl J Med 352: , 25 Boushey et al N Engl J Med 352: , 25 5
6 Inhaled Steroids - not Disease Modifying Inhaled Steroids - not Disease Modifying Triamcinalone Triamcinalone Salmeterol Salmeterol Triamcinalone Triamcinalone Sovijarvi et al. Thorax 58: 5 54, 23. Lazarus et al. JAMA 285: , 21 Q2: Your patient has 3-4 exacerbations/yr. Between exacerbations she s asymptomatic. Treat her with: 1. Regular ICS 2. Regular ICS only when symptomatic 3. Prn ICS 55% N = 7,241, ages 5-66 The START Study Mild asthma; symptoms weekly; <2 years Baseline Pre-Bronchodilator FEV1 ~86% Baseline Post-Bronchodilator FEV1 ~97% Intervention: Budesonide DPI, 2-4 mcg 1x/day vs X 3 years 33% 12% Outcomes: *Budesonide reduced Exacerbations *Budesonide reduced decline in FEV Pauwels et al. Lancet 361: , 23 6
7 The START Study N = 7,241, ages 5-66 Mild asthma; symptoms weekly; <2 years Baseline Pre-Bronchodilator FEV1 ~86% Baseline Post-Bronchodilator FEV1 ~97% Intervention: Budesonide DPI, 2-4 mcg 1x/day vs X 3 years Do Exacerbations Contribute to Decline of Lung Function Over Time in Asthma? Outcomes: *Budesonide reduced Exacerbations *Budesonide reduced decline in FEV1 Pauwels et al. Lancet 361: , 23 Asthma Exacerbations Lead to Loss of Lung Function Asthma Exacerbations Lead to Loss of Lung Function Budesonide Budesonide Change in FEV1 (%) over 3 yrs -5 P=.57 No SARE SARE Change in FEV1 (%) over 3 yrs -5 P=.12 No Systemic Steroids P<.1 P<.1 Systemic Steroids P<.42 P= O Byrne et al. Am J Respir Crit Care Med 179:19-24, 29 O Byrne et al. Am J Respir Crit Care Med 179:19-24, 29 7
8 FACET: Changes Associated with Exacerbations FACET: Changes Associated with Exacerbations Tattersfield et al. Am J Respir Crit Care Med 16: , 1999 Tattersfield et al. Am J Respir Crit Care Med 16: , 1999 Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma Prn BDP/S Regular BDP Regular BDP/S Prn S Is High-Dose Fixed ICS dosing Necessary? Sx-Guided Management as an Alternate Approach Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma Purpose: to compare three treatments: Bud/FM 8/4.5 2X/d + prn Terbutaline Bud 32 2x/d + prn Terbutaline Bud/FM 8/4.5 2x/d + prn Bud/FM 8/4.5 Outcomes: Time to first exacerbation; number of exacerbations Symptoms, nocturnal awakenings, AM PEF, FEV1 Subjects: 276 adults and children with moderately severe asthma (mean FEV1 = 73% predicted) Papi et al. N Engl J Med 27;356: O Byrne P, et al. Am J Resp Crit Care Med 25; 171:
9 Time to First Exacerbation Inhaled Corticosteroids O Byrne P, et al. Am J Resp Crit Care Med 25; 171: Fanta, CH N Eng J Med 36:12-14, 29 Inhaled Long-Acting ß-Agonists Q3: I routinely give Pneumovax to: 1. All patients with severe asthma 2. Elderly asthmatics 3. Asthmatics with co-morbid conditions 4. All asthmatics years old 6% 3% Fanta, CH N Eng J Med 36:12-14, 29 7% 2%
10 Asthma and Pneumococcal Infections Asthma and Pneumococcal Infections Asthma is an independent risk factor for invasive pneumococcal disease. - nested case-control study - 2 to 49 years old - Tennessee Medicaid ( ) Talbot et al N Eng J Med 352:282-9, 25 Adults with asthma may be at increased risk for serious pneumococcal disease - (OR, 6.7; 95% CI, ; P =.1) - retrospective case-control study - Rochester Minnesota ( ) Juhn et al J Allergy Clin Immunol 122:719-23, 28 Possible Mechanisms: Disrupted airway epithelial barrier Increased and aberrant mucus production Alterations in innate and adaptive immunity Genetic factors Immunosuppressive medications Increased pneumococcal colonization Asthma and Pneumococcal Vaccination October 25, 28: The U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously yesterday to recommend that adults ages 19 to 64 with asthma receive pneumococcal polysaccharide vaccine (PPSV23) Aspirin and Asthma Worsens AERD (Triad Asthma) New asthma less likely among women who used 1 aspirin frequently (Nurses Health Study) 22% reduction in asthma incidence in men randomized to aspirin QOD (Physicians 2 Health Study) 1% reduction in asthma incidence in women randomized to aspirin QOD (Womens Health 3 Study) 1 Barr et al: Am J Respir Crit Care Med 169:836, 24 2 Barr et al: Am J Respir Crit Care Med 175:12, 27 3 Kurth et al: Thorax Jun;63:514, 28 1
11 Vitamin D and Asthma Vit D has potent immunomodulatory effects Vit D inhibits TH1,?TH2, induces IL-1, Tregs Maternal Vit D intake during pregnancy inversely associated with asthma symptoms in early childhood Camargo et al: Am J Clin Nutr 85:788, 27, 27 Vit D inversely associated with markers of asthma and allergy severity - IgE, eosinophils - Methacholine reactivity - Asthma hospitalization - Medication requirements Brehm et al: Am J Respir Crit Care Med 179:765, 29 Q4: Your patient has poor asthma control, despite high-dose ICS, LABA, LTRA. Which approach is now reasonable? 1. Empiric anti-reflux treatment (PPI) hr ph monitoring, to guide PPI tx 3. Careful history of GERD, to guide PPI 55% tx 11% 34% Treatment with a PPI does not improve asthma control in patients with poorly controlled asthma and asymptomatic GERD 11
12 COPD COPD = Inflammatory Disease Mortality is increasing (6th --> 1st; esp. women) Spirometry detects COPD without symptoms Smoking Cessation modifies natural history (lung function, mortality) Pharmacologic Therapy: ( it s not just for symptoms anymore ) - exacerbations, natural history? Pulmonary Rehab: reduces symptoms, depression, health care utilization; improves Q of L, exercise Deaths per 1, Age-Adjusted Death Rates for COPD, U.S., White Male Black Male White Female Black Female Percent Change in Age-Adjusted Death Rates (US, ) Proportion of 1965 Rate CHD Stroke Other CVD COPD All other causes Q 5: Which of the following has been shown to slow the loss of lung function in COPD? 1. Smoking Cessation 2. Salmeterol, Fluticasone, SM/FP 3. Tiotropium 4. All of the above 55% 41% % 64% 35% +163% 7% % 4%
13 . Effect of Smoking Cessation on FEV 1 Post Bronchdilator FEV 1 (liters) Sustained Quitters Continuing Smokers Effects of a Smoking Cessation Intervention on 14.5-year Mortality 2.4 Screen Follow-up in years JAMA 272:1497,1994. Anthonisen et al Ann Intern Med 25; 142: Effects of a Smoking Cessation Intervention on 14.5-year Mortality Effects of a Smoking Cessation Intervention on 14.5-year Mortality P=.1 P=.3 Anthonisen et al Ann Intern Med 25; 142: Anthonisen et al Ann Intern Med 25; 142:
14 Effects of a Smoking Cessation Intervention on 14.5-year Mortality % Subjects Abstinent Weeks Continuous Abstinence with Varenicline (Chantix ) OR (95% CI, ; P<.1) OR (95% CI, ; P<.1) N=3659; 1 cigs/day; mean = 21/day x 25 yrs Treated x 12 weeks 6 5 OR (95% CI, ; P<.1) OR (95% CI, ; P<.1) Chantix 1 BID Bupropion SR 4 44 P< P= Anthonisen et al Ann Intern Med 25; 142: Gonzales et al, JAMA 296: 47-55, 26 Jorenby et al, JAMA 296: 56-63, 26 % Subjects Abstinent Weeks Continuous Abstinence with Varenicline (Chantix ) OR (95% CI, ; P<.1) OR (95% CI, ; P=.57) N=3659; 1 cigs/day; mean = 21/day x 25 yrs Treated x 12 weeks 3 25 OR (95% CI, ; P<.1) OR (95% CI, ; P=.4) Chantix 1 BID Bupropion Smoking Cessation P= P= Gonzales et al, JAMA 296: 47-55, 26 Jorenby et al, JAMA 296: 56-63, 26 14
15 Inhaled Corticosteroids and COPD Lung Health Study II Decrease in FEV1/year STUDY SITES COMPARISON SMOKERS QUITTERS Lung Health Study US + Canada Smokers vs Quitters 62 ml 32 ml STUDY SITES COMPARISON PLACEBO STEROID Copenhagen City Denmark BUD vs PBO 42 ml 42 ml EUROSCOP Europe BUD VS PBO 69 ml 57 ml ISOLDE Europe FP vs PBO 59 ml 5 ml Lung Health Study II US + Canada TAC vs PBO 47 ml 44 ml Change from Baseline FEV 1 (ml) (after bronchodilator) Triamcinolone (6 µg bid) Follow-up (years) NEJM 2; 343: COPD Exacerbations (Lung Health II) COPD Exacerbations (ISOLDE - stratified by FEV 1 ) Respiratory Exacerbations (per 1 person-years) p = Triamcinolone Fluticasone * < >1.54 FEV1 (liters) * NEJM 2; 343: Burge et al. Br Med J. 2; 32:
16 Effects of Inhaled Corticosteroids in COPD: Meta-Analysis Relative Risk of Exacerbations in Patients With COPD Treated With Inhaled Corticosteroids vs Author Vestbo et al Bourbeau et al Burge et al Lung Health Study Weir et al Paggiaro et al Overall What is the Role of Inhaled Bronchodilators in COPD?..5 Relative Risk Alsaeedi A et al. Am J Med. 22;113: % of COPD patients with 15% in FEV 1 (Days 1, 29, 57 &/or 85) FEV 1 : Tiotropium vs. Day 1 Day 8 Day 92 Day Tiotropium (n=518) 1.2 FEV 1 (L) (n=328) Time (minutes) Dorinsky et al. Chest 1999; 115: Casaburi R et al. Eur Respir J 22; 19:
17 Tiotropium Reduces Exacerbations and Hospitalizations vs Ipratropium Tiotropium reduces Exacerbations in COPD Probability of no hospitalization Tiotropium Ipratropium Time to first hospitalization: P=.48 Days on treatment Probability of no exacerbations Tiotropium Ipratropium Time to first exacerbation: P=.8 Days on treatment Niewoehner et al Annals Int Med 143:317-26, 25 Vincken W et al. Eur Respir J. 22;19: Tiotropium reduces Exacerbations in COPD Niewoehner et al Annals Int Med 143:317-26, 25 Salmeterol and Fluticasone Proprionate and Survival in COPD (TORCH) N = years old; 1 pack-years FEV1 < 6% predicted; FEV1/FVC.7 Salmeterol 5mcg BID vs Fluticasone 5mcg BID vs Salmeterol 5/Fluticasone 5 BID vs Calverley NEJM 27; 356: X 3 years Primary Outcome: Death from All Causes 17
18 TORCH TORCH Calverley NEJM 27; 356: Celli et al Am J Respir Crit Care Med 178:332-38, 28 Health Status (SGRQ) TORCH (UPLIFT) Calverley NEJM 27; 356: Tashkin et al NEJM 359: , 28 18
19 1 Survival in Hypoxic COPD Patients using Oxygen (UPLIFT) Cumulative Survival (%) NOTT (24h) NOTT (12h) MRC (15h) MRC (controls) Tashkin et al NEJM 359: , Time (years) AIM 93:391, 198 Lancet 1:681, Downward Spiral In Function Associated With COPD Disease Dyspnea Inactivity Deconditioning 19
Update on Asthma & COPD. Stephen C. Lazarus, M.D. Division of Pulmonary & Critical Care Medicine University of California San Francisco
Update on Asthma & COPD Stephen C. Lazarus, M.D. Division of Pulmonary & Critical Care Medicine University of California San Francisco Advances in Primary Care Medicine October 27, 29 Disclosures No Pharma
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationControversies in Clinical Trials
Controversies in Clinical Trials Christopher B Cooper, MD Professor of Medicine and Physiology David Geffen School of Medicine Medical Director, UCLA COPD Center Methodological issues discussed Pitfalls
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationDisclosures. Case #1 - Asthma. Question #1 Asthma. Update on Asthma & COPD. No Pharma Consulting, Research, Lectures
Update on Asthma & COPD Disclosures No Pharma Consulting, Research, Lectures NHLBI - Asthma Clinical Research Netwk Stephen C. Lazarus, M.D. Division of Pulmonary & Critical Care Medicine Cardiovascular
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationDisclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network
Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationDebating the use of inhaled corticosteroids in the treatment of COPD. COPD Epidemiology. A quick patient case. Risk Factors for COPD 1,2
Debating the use of inhaled corticosteroids in the treatment of COPD Suzanne G. Bollmeier Pharm.D., BCPS, AE-C Associate Professor, St. Louis College of Pharmacy ACPE Guidelines on Non- Commercialism o
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP/8197/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT
More informationDisease progression in COPD:
Disease progression in COPD: What is it? How should it be measured? Can it be modified? Professor Paul Jones MD, PhD, FERS Emeritus Professor of Respiratory Medicine; St George s, University of London
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationShaping a Dynamic Future in Respiratory Practice. #DFResp
Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationChallenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products
Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products Tushar Shah, M.D. Sr. VP, Global Respiratory Research and Development TEVA Pharmaceuticals 1 Presentation
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationObjectives. Asthma in Primary Care. Definition. Epidemiology. Pathophysiology
Objectives Asthma in Primary Care Jed Grant, PA-C Program Director, SJVC PA Program Staff PA, AMCH Emergency Department Apply the NAEPP guideline measures of severity and control including current impairment
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationOptimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center
Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking
More informationTreatment choices for patients with asthma or COPD. Jo Riley Lead Nurse For Oxfordshire Respiratory Service
Treatment choices for patients with asthma or COPD Jo Riley Lead Nurse For Oxfordshire Respiratory Service What is the difference? Is it all about? Inhaled steroids Long acting ß2 agonists Short acting
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationAsthma ASTHMA. Current Strategies for Asthma and COPD
Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationMethacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges
Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges AAAAI San Antonio Tx February 2013 Catherine Lemière MD, MSc Hôpital du
More informationPrimary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationEvidence-based recommendations or Show me the patients selected and I will tell you the results
Respiratory Medicine (2006) 100, S17 S21 Evidence-based recommendations or Show me the patients selected and I will tell you the results Leif Bjermer Department of Respiratory Medicine & Allergology, 221
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationAdult asthma management: focus on control
Adult asthma management: focus on control Jennifer W. McCallister, MD Associate Professor Pulmonary, Allergy, Critical Care & Sleep Medicine The Ohio State University Wexner Medical Center Objectives Apply
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationAsthma in Pregnancy. Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA. Introduction
Asthma in Pregnancy Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA Introduction Asthma is the most common potentially serious medical problem to complicate
More informationSafety of β2-agonists in asthma
Safety of β2-agonists in asthma Sanjeeva Dissanayake IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Overview Origin of concerns Mechanistic hypotheses Large scale clinical datasets Interpretation
More informationASTHMA PROTOCOL CELLO
ASTHMA PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives, non medical and medical therapy and a scheme for inhaler dosage.
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationAsma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli
Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre 2015 Overlap asma BPCO Dr. Marco Contoli Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara (Sept.
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationTreatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes
Patient Related Outcome Measures open access to scientific and medical research Open Access Full Text Article Review Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationAcute exacerbations of chronic obstructive
Eur Respir Rev 2005; 14: 95, 78 82 DOI: 10.1183/09059180.05.00009507 CopyrightßERSJ Ltd 2005 Modulation of airway inflammation to prevent exacerbations of COPD M. Solèr ABSTRACT: Exacerbations of chronic
More informationDisclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015
Disclosure Asthma: A GINA Update to the NAEPP 2007 Guidelines Robert (RC) Hellinga, Pharm.D. PGY 1 Pharmacy Resident Wolfson Children s Hospital/Baptist Health I do not have a vested interest in or affiliation
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationQ: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationImproving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationCOPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center
COPD UPDATE 2012 ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center Definition of COPD COPD is a preventable and treatable disease with some significant extra pulmonary effects that
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationWhat is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018
What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 No disclosures Disclosures objectives How to diagnose & Assess severity Treatment: Pharmacologic Non-Pharmacologic Maintenance
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides
BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper
More information